Abbott Laboratories (ABT) : Bryn Mawr Trust Co scooped up 4,450 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 10, 2016. The investment management firm now holds a total of 513,634 shares of Abbott Laboratories which is valued at $23,134,075.Abbott Laboratories makes up approximately 1.42% of Bryn Mawr Trust Co’s portfolio.
Other Hedge Funds, Including , Cetera Advisor Networks reduced its stake in ABT by selling 3,817 shares or 10.96% in the most recent quarter. The Hedge Fund company now holds 31,021 shares of ABT which is valued at $1,397,186. Abbott Laboratories makes up approx 0.08% of Cetera Advisor Networks’s portfolio. De Burlo Group Inc sold out all of its stake in ABT during the most recent quarter. The investment firm sold 5,000 shares of ABT which is valued $226,300.American Research Management reduced its stake in ABT by selling 525 shares or 21.03% in the most recent quarter. The Hedge Fund company now holds 1,972 shares of ABT which is valued at $88,247. Abbott Laboratories makes up approx 0.03% of American Research Management’s portfolio. Ariel Capital Advisors added ABT to its portfolio by purchasing 18,150 company shares during the most recent quarter which is valued at $792,611. Abbott Laboratories makes up approx 0.48% of Ariel Capital Advisors’s portfolio.
Abbott Laboratories closed down -0.12 points or -0.27% at $44.24 with 94,39,877 shares getting traded on Friday. Post opening the session at $44.17, the shares hit an intraday low of $43.645 and an intraday high of $44.31 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.